PharmacoEconomics & Outcomes News

, Volume 817, Issue 1, pp 33–33 | Cite as

Small gain of regorafenib too costly in advanced HCC

Clinical study


  1. Shlomai A, et al. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib - A cost-effectiveness analysis. PLOS One : 8 Nov 2018. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations